loadpatents
name:-0.014871835708618
name:-0.01509690284729
name:-0.0037229061126709
Kunkel; Steven L. Patent Filings

Kunkel; Steven L.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Kunkel; Steven L..The latest application filed is for "stem cell factor inhibitor".

Company Profile
2.16.12
  • Kunkel; Steven L. - Ann Arbor MI
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Stem Cell Factor Inhibitor
App 20220017613 - Lukacs; Nicholas W. ;   et al.
2022-01-20
Therapeutic Antibodies And Uses Thereof
App 20200255509 - Kind Code
2020-08-13
Antibody targeting stem cell factor
Grant 10,501,535 - Lukacs , et al. Dec
2019-12-10
Stem Cell Factor Inhibitor
App 20180030129 - Lukacs; Nicholas W. ;   et al.
2018-02-01
Stem cell factor inhibitor
Grant 9,790,272 - Lukacs , et al. October 17, 2
2017-10-17
Therapeutic Antibodies And Uses Thereof
App 20160257742 - LUKACS; NICHOLAS W. ;   et al.
2016-09-08
Stem Cell Factor Inhibitor
App 20160251423 - Lukacs; Nicholas W. ;   et al.
2016-09-01
Stem cell factor inhibitor
Grant 9,353,178 - Lukacs , et al. May 31, 2
2016-05-31
Therapeutic Antibodies And Uses Thereof
App 20150018408 - Lukacs; Nicholas W. ;   et al.
2015-01-15
Stem cell factor inhibitor
Grant 8,911,729 - Lukacs , et al. December 16, 2
2014-12-16
Methods for treating pulmonary fibrosis
Grant 8,795,668 - Hogaboam , et al. August 5, 2
2014-08-05
Stem Cell Factor Inhibitor
App 20140023651 - Lukacs; Nicholas W. ;   et al.
2014-01-23
Stem Cell Factor Inhibitor
App 20120321629 - Lukacs; Nicholas W. ;   et al.
2012-12-20
Biomarkers Predictive Of Progression Of Fibrosis
App 20120282276 - Hogaboam; Cory ;   et al.
2012-11-08
Chimeric molecule for the treatment of th2-like cytokine mediated disorders
Grant 7,541,040 - Puri , et al. June 2, 2
2009-06-02
Treatment of idiopathic pulmonary fibrosis using IP-10
Grant 7,265,083 - Strieter , et al. September 4, 2
2007-09-04
Materials and methods for treating chronic fibrotic diseases
App 20070172856 - Hogaboam; Cory M. ;   et al.
2007-07-26
Chimeric molecule for the treatment of th2-like cytokine mediated disorders
App 20050142105 - Puri, Raj K ;   et al.
2005-06-30
Treatment of liver disease and injury with CXC chemokines
Grant 6,719,969 - Hogaboam , et al. April 13, 2
2004-04-13
Treatment of idiopathic pulmonary fibrosis using IP-10
App 20030031645 - Strieter, Robert M. ;   et al.
2003-02-13
Method for treating asthma using SCF antibody
Grant 5,911,988 - Brownell , et al. June 15, 1
1999-06-15
CXC chemokines as regulators of angiogenesis
Grant 5,871,723 - Strieter , et al. February 16, 1
1999-02-16
Radiolabeled neutrophil activating peptides for imaging
Grant 5,605,671 - Lyle , et al. February 25, 1
1997-02-25
Therapeutic treatment for inhibiting vascular restenosis
Grant 5,571,713 - Lyle , et al. November 5, 1
1996-11-05
Labelled monocyte chemoattractant protein material and medical uses thereof
Grant 5,413,778 - Kunkel , et al. May 9, 1
1995-05-09
Labelled interleukin-8 and medical uses thereof
Grant 5,346,686 - Lyle , et al. September 13, 1
1994-09-13
Company Registrations

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed